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THE EFFECT OF LOCAL ANAESTHETIC WOUND INFILTRATION ON
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CONTROLLED TRIAL
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Purpose: Most patients who have hip replacement do so to relieve pain
and stiffness associated with osteoarthritis. However, around 10% of
patients who have total hip replacement report chronic pain related to
their operated joint 3 months after surgery. It is important to identify
ways to reduce the chance that patients will have this type of ongoing
pain. A known risk factor for chronic post-surgical pain is the severity of
acute post-operative pain. There is evidence that local anaesthetic
wound inﬁltration reduces acute post-operative pain; however, it is
uncertain whether it is also effective at reducing chronic pain in the
long-term. The aim of this randomised controlled trial (RCT) was to
determine if local anaesthetic wound inﬁltration could signiﬁcantly
reduce the severity of joint pain at 12-months after total hip
replacement.
Methods: This study was a double-blind randomised controlled trial of
patients undergoing primary total hip replacement for osteoarthritis at
a high volume elective orthopaedic centre in the UK. Patients were
randomised to receive additional intra-operative local anaesthetic
wound inﬁltration or the standard anaesthesia regimen alone. The
usual anaesthesia regimen consisted of spinal or general anaesthetic,
depending on patient clinical factors. Patients in the intervention group
received an added injection of 60 mls of 0.25% bupivacaine with 1 in
200,000 adrenaline at the wound site before surgical closure. Post-
operative pain management was the same for the intervention and
usual care group, and included a patient-controlled analgesia device.
Randomisation was minimised by baseline hip pain severity and sur-
gical approach. The primary outcome was pain at 12-months post-
operative measured by the WOMAC Pain scale. Secondary outcomes
included the WOMAC Function and Stiffness scales, the Intermittent
and Constant Osteoarthritis Pain (ICOAP) measure and the PainDETECT
(a measure of neuropathic pain), collected by postal questionnaires
administered at 3-months, 6-months and 12-months after surgery.
Measurements of daily acute post-operative pain severity were col-
lected on post-operative days 1-3 using a visual analogue scale. Com-
plications and adverse events were collected from patients’ self-report
at 3-months and 12-months and a review of medical records. WOMAC
Pain scores at 12-months post-operative were categorised into “No
pain”; “Mild”; “Moderate” and “Severe” and analyzed using generalized
ordered logit models in an intent-to-treat approach. Results are pre-
sented as odds ratios and 95% conﬁdence intervals (CIs). Secondary
outcomes were analysed using generalised linear models and general-
ized linear mixed models.
Results: 639 eligible patients were approached to take part in this study
and 322 consented to participate (50% recruitment rate). Prior to sur-
gery, 163 patients were randomised to the intervention group and 159
to the standard care group. Patients receiving additional local anaes-
thetic wound inﬁltration were less likely to report severe pain at 12-
months post-operative compared with patients receiving the usual
anaesthetic regimen alone (OR¼0.13; 95% CIs¼0.03, 0.62; p¼0.011). At
12-months post-operative, patients in the intervention group were also
less likely to report neuropathic pain on the PainDETECT questionnaire
(OR¼0.22; 95% CIs¼0.05, 0.97; p¼0.046). No differences were observed
for outcomes assessed through ICOAP, WOMAC function or WOMAC
stiffness questionnaires. During their inpatient stay, patients of both
groups reported comparable levels of daily pain, with the exception of
pain on the second post-operative night (Coef.¼ -0.83; 95% CIs -1.41,
-0.26; p¼0.005). Complications and adverse events were similar
between the intervention and standard care groups.
Conclusions: This is the ﬁrst RCT to assess the longer-term effects of a
local anaesthetic wound inﬁltration on pain severity after hip replace-
ment. We found that local anaesthetic wound inﬁltration administered
before wound closure is effective in reducing the number of patients
experiencing severe pain at 12-months after hip replacement. There
was also some evidence of reductions in neuropathic pain at 12-monthspost-operative and pain on the second post-operative night for patients
in the intervention group compared with the usual care group. We
recommend the addition of local anaesthetic wound inﬁltration to the
usual anaesthesia regimen during primary total hip replacement sur-
gery to reduce the risk of severe chronic pain after surgery.
6
EFFECTIVENESS OF EXERCISE THERAPY ADDED TO GENERAL
PRACTITIONERS’ CARE VERSUS GENERAL PRACTITIONERS’ CARE
ALONE IN PATIENTS WITH HIP OSTEOARTHRITIS
C. Teirlinck y, P. Luijsterburg y, J. Dekker z, A. Bohnen y, P. van Es y,
J. Verhaar y, M. Koopmanschap x, B. Koes y, S. Bierma-Zeinstra y.
y Erasmus MC, Erasmus Univ. Med. Ctr., Rotterdam, Netherlands; zVU
Med. Ctr./EMGO Inst., Amsterdam, Netherlands; x Erasmus Univ.
Rotterdam, Rotterdam, Netherlands
Purpose: The main goal of this comparative study was to investigate
whether exercise therapy added to general practitioners’ care is effec-
tive compared to general practitioners’ care only in patients with a new
episode of hip OA in general practice, over a period of 12 months.
Methods: Study design used was a randomized controlled trial with a
parallel group design. Patients could participate the trial if they were 45
years or older, comply with the clinical American College of Rheuma-
tology criteria for hip OA, and visited their general practitioner for a new
episode of complaints due to hip osteoarthritis. Patients were excluded
if they: 1) were already treated with exercise therapy in the present
episode of hip OA, 2) had a hip pain score of<2 on the 11-point numeric
rating scale (0 to 10), 3) had a high level of physical function, a score of
<2 on the walking ability and the physical function sections of the
Algofunctional index, 4) had undergone hip surgery or those on the
waiting list for surgery, 5) had severe disabling co-morbidity and 6) had
insufﬁcient comprehension of the Dutch language and/or were men-
tally incapable of participation. The patients were randomized using
sealed envelopes based on a computer generated random table in two
treatment groups: one group received exercise therapy supervised by a
physiotherapist added to general practitioners’ care and the control
group received general practitioners’ care only. The exercise therapy
consisted of up to 15 sessions in the ﬁrst threemonths and three follow-
up (booster)sessions in month ﬁve, seven and nine. The primary out-
comesmeasured for the clinical studywere severity of hip pain and hip-
related function measured with the Hip disability Osteoarthritis Out-
come Score (HOOS). Secondary outcome measures were: severity of hip
pain averaged over past week measured with an 11-point numerical
rating scale, severity of intermittent and constant hip pain measured
with the Intermittent and Constant Osteoarthritis Pain (ICOAP) ques-
tionnaire, functional mobility measure with the timed Up and Go test,
patients’ perceived recovery measured with a 7-point Likert scale,
quality of life measuredwith the EQ-5D instrument. The patients scored
the outcomes using questionnaires at 6 weeks and at 3, 6, 9 and 12
months after baseline measurement. All analyses were performed
according to intention to treat principle. We used linear mixed models
analysis with repeated measurements and adjusted the analysis for age
and body mass index.
Results: The study took place in the period 2009-2012 and 203 patients
from 101 general practitioners participated. The mean age was 65 years
and there were slightly more women (60%) than men. Randomly allo-
cated to the exercise group were 101 patients and 102 patients to the
group that received general practitioners’ care only. At baseline both
groups were quite similar, however, the number of patients who
reported performing unsupervised hip exercises prior to baseline was
15% higher in the control group. In addition, the number of patients
reporting using pain medication daily prior to baseline was 10% higher
in the control group. Therefore, besides age and body mass index,
analyses were also adjusted for these two variables. Regarding com-
pliance: 97 (96%) of the patients in the exercise group had visited a
physiotherapist. Mean number of visits was 9 (SD 4.0). Forty-eight
patients (48%) had 1 booster session, 46 (46%) 2 booster sessions and 36
(36%) received all three prescribed booster sessions. In the control
group, 14 (14%) patients had visited a physiotherapist (mean visits: 8;
SD 6.2). At 3 months follow-up there were statistically signiﬁcant and
clinically relevant differences between the groups on the primary
outcomes HOOS pain -3.9 (95%CI -7.7;-0.1: p-value of 0.04) and HOOS
function -5.2 (95%CI -9.1;-1.2: p-value of 0.01) in favor of the patients
who received the exercise therapy. However, this effect was no longer
present after 12 months follow-up. The analyses showed the same for
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istically signiﬁcant and clinically relevant differences between the
groups at 3 months but not at 12 months follow-up), but not for the
other outcomes (no differences between the groups at 3 months and at
12 months follow-up). No adverse events were reported during the
study.
Conclusions: At 3 months follow-up there was a statistical signiﬁcant
difference between the treatment groups in favor of the group allocated
to exercise therapy on the primary outcomes HOOS pain and HOOS
function and also in the secondary outcome ICOAP. At 12 months fol-
low-up there were no statistical differences between the treatment
groups.
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Purpose: Throughout our lifespan, maintenance of synovial joint
integrity is essential for quality of life. While much is known about the
susceptibility of synovial joints to common pathologies such as age-
dependent and post-traumatic osteoarthritis, basic information about
their developmental biology is surprisingly limited. Previously, research
from our group demonstrated that Gdf5-expressing mesenchymal
interzone cells forming at presumptive limb joint sites give rise to
multiple joint tissues during embryonic development including artic-
ular cartilage, ligaments and synovial lining. What had remained
unknown, however, is whether spatiotemporal differences in genesis of
Gdf-5 expressing cells results in selective participation in development
of speciﬁc joint tissues, and what roles Gdf-5 expressing cells may have
in postnatal joint phenotype and function. To address these and related
questions, we carried out detailed Gdf-5 cell lineage tracing during late
embryonic and postnatal joint development using our existing Gdf5-
Cre mouse line as well as a novel Gdf5-CreERT2 line.
Methods: Female Gdf5-Cre transgenic mice were mated with male
ROSA-mTomato/mGFP (mTmG) reporter mice which express con-
stitutive red ﬂuorescence prior to, and conditional green ﬂuorescence
following, Cre-mediated recombination. Offspring were harvested at
embryonic day 18.5 (E18.5) and postnatal day 0, 14 or 28 (P0, P14 or
P28). Female mice from our new Gdf5-CreERT2 transgenic strain were
mated with male ROSA-tdTomato reporter mice which express red
ﬂuorescent protein in cells following Cre-mediated recombination.
Gdf5-CreERT2 females were injected with tamoxifen at E14.5 and E15.5,
and resulting embryos were harvested at E18.5.
Results: Cre-dependent lacZ reporter strains (ROSAR26R) are widely
used for cell lineage and fate map tracing. However, endogenous b-
galactosidase expression in postnatal skeletal tissues leads to back-
ground staining and difﬁculties in interpreting Cre expression patterns.
Indeed, b-galactosidase staining of sections from P14 Gdf-5Cre;R26R
mouse knees was present in bone areas (Figure 1A, arrows) in addition
to predicted expression patterns in articular cartilage (AC, arrowhead),
synovial lining (SL, arrowhead) and capsule tissue (CT, arrowhead). In
contrast, expression of mGFP in complementary Gdf-5Cre;ROSA-mTmG
mice was limited to articular cartilage, synovial lining and capsule tis-
sue (Figure 1B, arrowheads). When tamoxifenwas injected at E14.5 and
E15.5 in our novel Gdf5-CreERT2;ROSAtdTomato mice, we found that
selective labeling was present in superﬁcial articular cells and synovial
lining by E18.5 (Figure 2,A). In comparison, continuous joint progenitor
labeling in standard Gdf-5Cre;ROSA-mTmG mice generated broader
labeling of articular cell layers and synovial cells (Figure 2, B). To
monitor fate and function of labeled cells, Gdf-5Cre;ROSA-mTmG mice
were sacriﬁced at successive postnatal ages. In neonatal mice, mGFP-
expressing cells were present throughout the epiphyseal articular car-
tilage of femur, extending several cell layers below the articular surface
(Figure 2, C). Interestingly, the mGFP expression patterns became more
restricted by P14, with several mGFP-negative cells present in the two
most superﬁcial cell layers (Figure 2D). Patterns of decreasing expres-
sion at the articular surface continued through P28 (Figure 2E).
Conclusions: Our data demonstrate the exciting potentials of the new
novel Gdf5-CreERT2 mouse line for studying spatiotemporal Gdf-5
activation in developing joints and indicate that CreER activation atE14.5 and E15.5 elicits reporter expression conﬁned to the most
superﬁcial layer of developing E18.5 articular cartilage. The constitutive
Gdf5-Cre line instead elicits reporter expression in several articular
layers by the same age. Though preliminary, the data from the novel
Gdf5CreER line suggests that sub-populations of progenitor cells exist
within a broader region of cells labeled by Gdf5Cre, hinting at their
diverse joint formation capacity. Our data from postnatal Gdf-5Crex-
ROSAmTmG mice indicate that not all articular chondrocytes are
reporter positive by P14 and P28. One possibility is that reporter
expression was partially lost over time. A far more interesting possi-
bility is that there may be an additional source of postnatal articular
progenitors, such as the groove of Ranvier.8
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